1 / 24

Hematopoietic Malignacies

Hematopoietic Malignacies. Plasma Cell dyscrasias (Lymphomas). Common Issues in HCs. HC: ~ 10% of all malignacies (incidence/death) Lymphomas: 4% of all cancers mobility of cells genetic instability clonal expansion potential. HC: 45% NHL HC: 12% HL HC: 14% Myelomas HC: 29% Leukemias.

deborah-mcintosh
Télécharger la présentation

Hematopoietic Malignacies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hematopoietic Malignacies Plasma Cell dyscrasias (Lymphomas)

  2. Common Issues in HCs • HC: ~ 10% of all malignacies (incidence/death) • Lymphomas: 4% of all cancers • mobility of cells • genetic instability • clonal expansion potential

  3. HC: 45% NHL • HC: 12% HL • HC: 14% Myelomas • HC: 29% Leukemias

  4. Historical notes 1750s: Robert Virchow: “leukemia” 1850s: Thomas Hodgkin: H.Disease 1950s: HD as Hlymphoma 1950s: Peter Nowell+David Hungerford: abnormal short chromosome 22 in CML 1970s: Jenat Rowley, Chicago, increased chromosome 9 (22-> 9 translocation) + multiple other defects lymphoblastic lymphomas / lymphocytic lymphomas cancer stem cells (AML, tumor transfer studies)

  5. oncogenesis • Genetic (translocations / recurring translocations, mutations • environmental carcinogens (benzene, radiation) • secondary to intensive RxT, ChemoTher (for a primary cancer / in preparation for BMT or HCT)

  6. Clinical terms • Acute / chronic • high grade (transformed precursor cells); T1/2 ~ 24 months • medium / low grade (more mature phenotypes, 2 - 5 years) • clinical responses: complete remission (>4 weeks) / relapse; refractory to treatment / salvage therapy; LTS/residual disease in > 5 years

  7. therapeutics • Autologous HCT (G-CSF, leukaferesis, CD34+) • allogeneic BM, HLA-matched • biologicals: IFNalpha, mAbs anti CD19, CD20, CD22 (ADCC, complement CML), immunotoxins (diphteria toxin - IL2 for IL-2R+ T lymphomas; radiolabelling Yttrium 90, Iodine 131

  8. Plasma cell dyscrasias • M protein (paraprotein) • Monoclonal Gammapathy of Undetermined Significance (MGUS) • 1% of age > 40y • 70% asymptomatic; transitory • 25%: mild anemia => myelomas or B cell lymphomas

  9. Waldenstrom Macroglobulinemia large quantities of IgM paraproteins viscous blood => vision / neurologic signs accumulation of tumors BM, spleen, lymph nodes (>40%) anemia hemorrhaging cutaneous lesions (cells / deposits) unlike lymphomas: not producing osteoclast activating factors; BM lesions less than 10% good response to purine analogues (cladribine)

  10. Myeloma • Often arise from preexisting MGUS by additional mutations • anemia • state of immunosuppression, infections • hypercoagulability • circulatory difficulties, pulmonary function reduced • neurological signs • many cases: excess of Bence Jones proteins

  11. Tam-Horshfall protein binding - aggregates promoting hypercalciuria and hypercalcemia; interstitial nephritis (kidney failure) • 4/100 000 (age, sex, race); HLA-Cw2 • ionizing radiation • classification: multiple criteria • DEREGULATION in CYTOKINES

  12. IL-6 appear to autodrive the cancer STAT-3: upregulation of Bcl-xL; upregulation Myeloid Cell Factor 1 (MCL-1, essential for tumor cell survival) induces VEGF in myeloma cells: promotes angiogenesis, migration of tumor cells, IHIBITS Ag presentation by DCs IL-6+MIP-1a+IL-1b+TNF => BM stromal cells produces OPGL, master regulator of osteoclastogenesis IL-2+IL-7+IL-11+Lta+GM-CSF => suppresses IgG, Th, NK TGFb: autocrine loop for IL-6 secretion IGF-1 of BM stromal cells=> PI3K / PKB(AKT) = > survival

  13. Genetics: many abnormalities Trisomy 6, 9(with more favourable prognosis) and 3, 5, 7, 11, 15, 19 13q deletions very poor prognosis 70%: Cdk mutations p15, p16 Cdk inhibitor / hypermethylation Ras oncogene activation (late stages); p53 (late stages)

  14. Early: translocation Ig H locus FGFR3 gene, 4p16 => fusion product blocks caspase-3 apoptosis IRF4 gene 67p21 cyclin D3 gene 6p21 Bcl-1 gene at 11q13 common upregulation of Bcl-2, Bcl-xL deletions of 13q14 (Rb tumor suppressor gene)

  15. Treatment: difficult 5 years survival < 30% early stages : INDOLENT alkylating agents (melphalan) + prednison alternative: dexamethasone, vincristine, thalidomide, adriamycin Thalidomide: activates caspase 8; blocks IL6, angiogenetic activity BORTEZOMIB (Velcade) proteosomal inhibitor, limits the catabolism of ubiquitinated proteins, including I-kB=> block IL6, induces apoptosis, decreases VEGF IGNa: remission, but not longer survival biphosphonates (osteoclast inhibitors: zolendronate, pamidronate)

More Related